Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Lutetium Lu 177 dotatate by Advanced Accelerator Applications for Pheochromocytoma: Likelihood of Approval
Lutetium Lu 177 dotatate is under clinical development by Advanced Accelerator Applications and currently in Phase II for Pheochromocytoma. According...
Data Insights
Lutetium Lu 177 dotatate by Eli Lilly and Co for Neuroendocrine Tumors: Likelihood of Approval
Lutetium Lu 177 dotatate is under clinical development by Eli Lilly and Co and currently in Phase III for Neuroendocrine...